Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients

Corneal Erosion Clinical Trial

Official title: A Clinical Study on the Safety and Efficacy of SHJ002 Sterile Ophthalmic Solution in the Treatment of Corneal Erosion in Patients With Sjogren's Syndrome

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to measure efficacy and safety with 0.25% SHJ002 sterile ophthalmic solution compared to vehicle in treating corneal erosion in Sjogren's patients. SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.

Clinical Trial Description

Participants will be randomized to treatment with SHJ002 Ophthalmic Solution or vehicle which will be administered to each eye twice daily for 12 weeks. ;

Related Conditions & MeSH terms

• Corneal Erosion

• NCT number: NCT06381986
• Study type: Interventional
• Source: Sunhawk Vision Biotech, Inc.
• Contact: Suh-Hang H. Juo, MD, Ph.D.
• Phone: +886-975357586
• Email: hjuo@shvbiotech.com
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: May 2024
• Completion date: February 2025